Navigation Links
Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
Date:11/1/2008

r, which can lead to fibrosis and cirrhosis, and may ultimately lead to liver failure and/or liver cancer if not successfully treated. Cirrhosis of the liver resulting from chronic HCV infection is the leading indication for liver transplantation in the U.S. Due to the asymptomatic nature of HCV infection, it often goes undetected for up to 20 years following initial infection. Each year, 8,000 to 10,000 people in the U.S. die from complications of HCV.

The current standard of care is a combination of pegylated interferon and ribavirin. Inadequate response rates, in particular for patients infected with genotype 1 HCV, along with significant side effects of approved therapy, support the medical need for improved treatment options. It is estimated that fewer than 5% of people with chronic HCV infection living in the U.S. are under treatment today. Most infected individuals are unaware of their infection status and the large majority of individuals who know their condition do not currently receive drug therapy. There is also a growing number of individuals who have failed interferon-based regimens who may be successfully treated with combinations of two or more direct antivirals. It is expected that the next generation of therapies for treatment of HCV will include small molecules, such as ANA598, that directly act upon specific viral enzymes to inhibit viral replication. These new therapies are expected to improve overall therapy by increasing cure rates and potentially improving tolerability and convenience of treatment if doses of currently used agents can be reduced or eliminated.

About Anadys

Anadys Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology. For the treatment of chronic hepatitis C, the Company is developing two potentially complementary agents, ANA598, a non-nucleoside polymerase inhibitor and ANA773, an oral T
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
2. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
3. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
6. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
7. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
8. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
9. Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor
10. Minster Pharmaceuticals Plc Announces Positive Results from Phase II Trial of Migraine with Aura
11. Addrenex Pharmaceuticals Initiates Phase 2 Trial on Its Novel Hypertension Drug, ADX415
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... -- Big Market Research presents a detailed analysis of ... , ( France , Germany , ... and Japan . Current scientific views on the ... 5-year test volume and sales forecasts by country for HAV NAT, ... Delta, HBc Ag, HBe Ag, and ALT/SGPT tests performed in the ...
(Date:5/5/2015)... China , May 5, 2015 Faced with ... rising public health awareness, China,s medical ... the markets with the largest demands have been ... Guangzhou and other first-tier cities. However, the entry ... short time makes these "high-end" markets in first-tier cities increasingly ...
(Date:5/5/2015)... RIDGEFIELD, Conn. , May 5, 2015 /PRNewswire/ ... abstracts from the company,s respiratory portfolio will be ... International Conference taking place May 15-20 in ... therapies for chronic obstructive pulmonary disease (COPD) and ... fibrosis (IPF) and COPD. Of the 29 accepted ...
Breaking Medicine Technology:2015 Opportunities in the Global Hepatitis Diagnostic Testing Market: Big Market Research 22015 Opportunities in the Global Hepatitis Diagnostic Testing Market: Big Market Research 3MEDITEXPO JIANGSU 2015 is to Help Medical Device Companies Explore Business Opportunities in Wider Markets 2MEDITEXPO JIANGSU 2015 is to Help Medical Device Companies Explore Business Opportunities in Wider Markets 3MEDITEXPO JIANGSU 2015 is to Help Medical Device Companies Explore Business Opportunities in Wider Markets 4Boehringer Ingelheim to Present 29 Abstracts at the Annual American Thoracic Society International Conference 2Boehringer Ingelheim to Present 29 Abstracts at the Annual American Thoracic Society International Conference 3Boehringer Ingelheim to Present 29 Abstracts at the Annual American Thoracic Society International Conference 4Boehringer Ingelheim to Present 29 Abstracts at the Annual American Thoracic Society International Conference 5Boehringer Ingelheim to Present 29 Abstracts at the Annual American Thoracic Society International Conference 6Boehringer Ingelheim to Present 29 Abstracts at the Annual American Thoracic Society International Conference 7Boehringer Ingelheim to Present 29 Abstracts at the Annual American Thoracic Society International Conference 8Boehringer Ingelheim to Present 29 Abstracts at the Annual American Thoracic Society International Conference 9Boehringer Ingelheim to Present 29 Abstracts at the Annual American Thoracic Society International Conference 10Boehringer Ingelheim to Present 29 Abstracts at the Annual American Thoracic Society International Conference 11Boehringer Ingelheim to Present 29 Abstracts at the Annual American Thoracic Society International Conference 12Boehringer Ingelheim to Present 29 Abstracts at the Annual American Thoracic Society International Conference 13Boehringer Ingelheim to Present 29 Abstracts at the Annual American Thoracic Society International Conference 14
... Medical Systems Ltd. (Nasdaq: DHRM ) ("Dehaier" or ... and sale of medical devices and homecare medical products in ... the first quarter of fiscal 2011 ended March 31, 2011 ... in the United States. Company management will ...
... LOUIS, April 27, 2011 Stereotaxis, Inc. (Nasdaq: ... of its new Stereotaxis Epoch™  platform, a comprehensive ... recognized benefits of remote magnetic catheter control, the ... power of the Odyssey platform, enabling highly sophisticated ...
Cached Medicine Technology:Dehaier Medical to Report First Quarter 2011 Financial Results on May 4 2Stereotaxis Introduces New Electrophysiology Platform: Epoch™ 2Stereotaxis Introduces New Electrophysiology Platform: Epoch™ 3Stereotaxis Introduces New Electrophysiology Platform: Epoch™ 4
(Date:5/5/2015)... 05, 2015 On May, 5, 2015, My ... musician Irene Rose about alternatives for youngsters to do this ... you get the idea for starting a summer camp and ... an entertainment company called Once Upon a Party and I ... through songs and even scripture. We play games, sing, and ...
(Date:5/5/2015)... RF Technologies®, a leading provider of personal safety ... Solution with Voice Alarms. The ST750 will play a ... wait for assistance when it detects them starting to ... different melodies or tones or silent alerting, by integrating ... Alert®. , For 28 years, Sensatec Fall Management ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 Major League ... with the belief that ultimate Frisbee™ is home to ... next sport that engages the world. Nike Ultimate Camps’ ... by creating opportunities for young athletes to learn about ... with MLU the perfect fit. , The Nike Ultimate ...
(Date:5/5/2015)... NovaSom, Inc., announced today that they ... with Ed Begley Jr., airing via Discovery Channel 3rd ... segment will focus on NovaSom, a leader in Obstructive ... their AccuSom® home sleep test, which is the only ... support and next-day test results and interpretation. , ...
(Date:5/5/2015)... Every year, news articles appear warning about the ... dry eye season is spring, also known as allergy season, ... United States. The only season offering a respite from seasonal ... of the Sharon Kleyne Hour™ Power of Water® radio show, ... May 11, 2015. Kleyne is the inventor of Nature’s Tears® ...
Breaking Medicine News(10 mins):Health News:My Positive Perspective Hosts Episode Informing People of a True Princess Summer Camp With Irene Rose 2Health News:RF Technologies® Releases Sensatec® ST750 Voice Alarm for Fall Management 2Health News:RF Technologies® Releases Sensatec® ST750 Voice Alarm for Fall Management 3Health News:US Sports Camps, Nike Ultimate Camps, and Major League Ultimate Host Youth Ultimate Summer Camps in Philidelphia 2Health News:Innovations with Ed Begley, Jr. to Explore NovaSom, Inc., in Upcoming Episode 2Health News:Nature’s Tears EyeMist tear film supplement soothes dry eye caused by spring pollen season, reports inventor Sharon Kleyne 2Health News:Nature’s Tears EyeMist tear film supplement soothes dry eye caused by spring pollen season, reports inventor Sharon Kleyne 3
... Robert I. Miller, a 25-year Siemens veteran, ... Industry Group within Siemens IT Solutions and Services, ... http://www.newscom.com/cgi-bin/prnh/20070904/SIEMENSLOGO )In this role, Miller will be ... business plan, including overall go-to-market activities, coordination with ...
... Palmetto GBA, a leading provider of technical and ... by the federal Centers for Medicare & Medicaid Services ... and perform related duties for South Carolina, North Carolina, ... process, CMS awarded Palmetto GBA a contract with a ...
... tomorrow,s (and even today,s) health problems may be found ... Consumer Electronics ShowLAS VEGAS, Jan. 9 /PRNewswire-USNewswire/ ... changing the way we shop, listen to music, and ... However, managing an illness or disability remains a frightening, ...
... strike fear in the hearts of men and those who ... shock of that diagnosis, suffered the grief and anger that ... of a lifetime. In his new book, "Life Begins at ... http://www.authorhouse.com ), he provides a valuable roadmap for those ...
... to Treat Diseases (HTDS) www.htdsmedical.com the company ... (Formerly ReNuYu Biochem) intends to recapitalize to 5 billion ... pending China Bio Chem merger. Consideration for Slavica is ... all doctors involved in Belgrade Serbia research. Key medical ...
... Jan. 8 New York City Mayor Michael R. ... and presented a proclamation to Ilchi Lee, president of ... Education, a revolutionary method of cognitive training to enhance ... is a globally-recognized thought leader regarding the power of ...
Cached Medicine News:Health News:Miller Joins Siemens IT Solutions and Services as V.P. of Healthcare Industry Group 2Health News:CMS Selects Palmetto GBA to Administer Medicare Program in Four States 2Health News:Meridian Makes CES Good For Your Health 2Health News:'Life Begins at 65: Words of a Cancer Survivor': New Book Offers Empowering Strategies for Rising Above Sickness and Setbacks 2Health News:'Life Begins at 65: Words of a Cancer Survivor': New Book Offers Empowering Strategies for Rising Above Sickness and Setbacks 3Health News:Hard To Treat Diseases (HTDS) Recapitalization 2Health News:NYC Mayor Michael R. Bloomberg Declares January 8th 'IBREA Brain Education Day' 2
... Tosoh Corporation launched the first generation HPLC ... HPLC/723Ghb brought a new level of automation ... forefront of diabetes testing in Japan. Now ... system, the G7 offers advanced automation; stable ...
... , Monoclonal antibody method for HbA1c ... study shows 99% agreement with the HPLC ... on a CV of 2.6%* means ... Standardization Program (NGSP) certified method, as recommended ...
... Maximize your laboratorys ... and enhanced automated workflow ... high-throughput automated workstation now ... and immunoassay with specimen ...
The sole coagulation analyzer in the world that uses a unique dry reagent card....
Medicine Products: